2000
DOI: 10.1016/s0014-2999(00)00053-4
|View full text |Cite
|
Sign up to set email alerts
|

A new look at the neuronal nicotinic acetylcholine receptor pharmacophore

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
13
0

Year Published

2002
2002
2014
2014

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 20 publications
(14 citation statements)
references
References 29 publications
1
13
0
Order By: Relevance
“…In this layer, we found a strong reaction for the a5 and b2 chains that are known to alter the pharmacological properties of the ACh-R (Gerzanich et al, 1998;Curtis et al, 2000), whereas the a3 and b4 chains were less frequently detected. The cytoplasmic colocalization of different heterooligomers in a single cell layer of the stratum granulosum has not been observed before.…”
Section: Discussionmentioning
confidence: 82%
“…In this layer, we found a strong reaction for the a5 and b2 chains that are known to alter the pharmacological properties of the ACh-R (Gerzanich et al, 1998;Curtis et al, 2000), whereas the a3 and b4 chains were less frequently detected. The cytoplasmic colocalization of different heterooligomers in a single cell layer of the stratum granulosum has not been observed before.…”
Section: Discussionmentioning
confidence: 82%
“…However, since in displacement affinity chromatography, binding affinities (K d values) are directly related to ml [31], and since with the nAChR there is a relationship between EC 50 and binding at the agonist binding site [8,9], comparative competitive displacement studies should be capable of the relative, qualitative determination of EC 50 values. As with the Cheng-Pursoff approach, the necessary requirements are that the agonists have an identical mechanism of action and that the experiments are performed under the same conditions.…”
Section: Resultsmentioning
confidence: 99%
“…The primary binding sites for agonists are located on the extracellular portion of the receptor in a pocket at the interface between the N-terminals of the ␣ and ␤ subunits [3,6,7]. One approach has been to construct pharmacophores of the agonist binding site [8,9] and to synthesize drug candidates which fit the conformational requirements of this site. This has led to the syntheses of conformationally constrained nicotine and anabasine analogues [10][11][12][13][14][15].…”
Section: Introductionmentioning
confidence: 99%
“…Chimeric and mutant ␣3/␣4 subunits were generated using a PCR-based method described previously (Curtis et al, 2000). A3(202)␣4 and ␣4(202)␣3 cDNAs were constructed through two successive PCRs (conditions identical to Curtis et al, 2000) by using the following primers: ␣3-F (5Ј-AGCTTATGGCTCT-GGCCGTCTC-3Ј); ␣3(202)␣4-R (5Ј-CATAGGTGATGTCGGGGTA-GATCTCC-3Ј); ␣3(202)␣4-F (complementary to ␣3(202)␣4-R); ␣4-R (5Ј-CGCACTTCCTAGATCATGCCAGCC-3Ј); ␣4-F (5Ј-TCGATCTA-GAGCCCGCGAGGTG-3Ј); ␣4(202)␣3-R (5Ј-GTGATGTCGGGGTA-GATCTCG-3Ј); ␣4(202)␣3-F (complementary to ␣4(202)␣3-R); and ␣3-R (5Ј-GCAAGGCAGGCACACAGCTTAG). The ␣4(588)stop cDNA was constructed using one PCR (conditions identical to first PCR described in Curtis et al, 2000) and the following primers: ␣4-F and ␣4(588)stop-R (5Ј-CTACTAGGGCGGTAGGAAGAGGC-3Ј).…”
Section: Drugs and Solutionsmentioning
confidence: 99%